Tesofensine is not a peptide: it is a small-molecule phenyltropane sold as capsules, tablets and oral solution. In the compound page's words, it “is not approved for human consumption, is active at sub-milligram doses, and carries a documented cardiovascular safety signal” — Phase II trials recorded dose-dependent increases in heart rate and blood pressure. This page does container arithmetic only; the compound is covered in the tesofensine guide.
A 0.5 mg tesofensine container — the labelled strength on three of its four lab tests — is 0.5 × $209.98 = $104.99 of compound at the median tracked price, and 0.5 × $159.78 = $79.89 at the lowest tracked (as of 21 Sep 2026). How many amounts it holds is 0.5 mg ÷ the amount you enter; tesofensine is active below a milligram, so an error of a few hundredths of a milligram in a label is a large share of the container.
Prices are the median and lowest tracked per milligram as of 21 Sep 2026, from lyophilised or bulk offers; a capsule or tablet sells at its own price, so enter your own product's strength as the container size.
Tesofensine has no injectable route in Peptigrity's sources, so this calculator prints no syringe units and no diluent step. It divides a labelled container by an amount you supply; the compound page states no dose.
Tesofensine has 4 independent lab tests on file at Peptigrity. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Tesofensine lab-test records.
Tesofensine (development code NS2330) is a small-molecule triple monoamine reuptake inhibitor that blocks reuptake of serotonin, norepinephrine and dopamine. It was developed by NeuroSearch for Alzheimer's and Parkinson's disease and repurposed as an anti-obesity candidate when trials showed unintended weight loss. It is not a peptide and not a GLP-1 drug. The table below is what the compound page states, as last updated in August 2026.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A phenyltropane small molecule, C17H23Cl2NO, 328.28 g/mol — not a peptide | Chemical identity |
| What form is it sold in? | Capsules, tablets and oral solution on the gray market; no injectable route is named | Market description |
| Human evidence? | A 2008 Phase II randomised trial (TIPO-1, n=203) published in The Lancet; development stalled | Human RCT (Phase II); older data |
| Safety signal? | Dose-dependent increases in heart rate and blood pressure; an elimination half-life on the order of ~220 hours | Human RCT (Phase II) |
| Approved anywhere? | Not approved by the FDA or EMA, and not finally approved anywhere as of August 2026 | None |
| A dose on Peptigrity? | “No. Tesofensine is not approved for human consumption, is active at sub-milligram doses, and carries a documented cardiovascular safety signal.” | None — declined |
The compound-specific caveat is scale. Because tesofensine is active below a milligram, the compound page notes that even small labelling or purity errors translate into large relative errors — which is why this calculator starts from the label on your container and treats every figure it prints as only as good as that label.
No syringe arithmetic, because nothing in Peptigrity's sources names an injectable route: the forms on sale are oral. No dose table, because the compound page declines the dose question in the sentence quoted above. The only milligram figures it carries are the arms of one trial, and they are reproduced here with their source, not as a schedule — the page states neither the frequency nor the route of administration used in the trial.
Peptigrity does not recommend a dose; these are the doses studied in the 2008 TIPO-1 Phase II trial, as the compound page (Last Updated: August 2026) reports them.
| Trial arm | Reported result | Duration | Source |
|---|---|---|---|
| 0.5 mg plus an energy-restricted diet | Mean 9.2% greater weight loss than diet and placebo | 24 weeks | TIPO-1, Phase II RCT, n=203, The Lancet (2008) |
| 1.0 mg plus an energy-restricted diet | 10.6% greater weight loss than diet and placebo | 24 weeks | TIPO-1, as above |
| Range across trials | Roughly 0.25 to 1 mg | — | Compound page, vendor-verification section |
The same trials documented the heart-rate and blood-pressure increases, dose-dependent, that the compound page names as the main reason US development did not advance. None of these figures is pre-filled in the calculator, and none is used as a divisor anywhere on this page.
The calculator does two divisions and two multiplications: amounts per container = label mg ÷ your amount; cost per amount = your amount × $/mg; container cost = label mg × $/mg. The form selector changes nothing in the arithmetic — a 0.5 mg capsule, tablet or bottle of solution is 0.5 mg of compound on its label. For an oral solution labelled in mg/mL, the container figure is that strength times the bottle's volume.
The label is the input, so how well labels hold up matters. The table lists the four tests on the compound page as of 21 September 2026, labelled against measured quantity; the percentage column is computed here.
| Test date | Labelled | Measured | Difference | Lab |
|---|---|---|---|---|
| 6 Aug 2026 | 0.25 mg | 0.27 mg | +8% | ILS Laboratories |
| 18 Jun 2026 | 0.5 mg | 0.52 mg | +4% | ILS Laboratories |
| 25 Mar 2026 | 0.5 mg | 0.54 mg | +8% | Vanguard Laboratory |
| 22 Feb 2026 | 0.5 mg | 0.518 mg | +3.6% | Ethos Analytics |
All four measured above label, by +3.6% to +8%, so for these four containers an amounts-per-container figure worked from the label is a floor. Four results are four data points, not a fill-variance distribution; a fifth container could sit under its label. Why label and delivered mass diverge: why 10 mg isn't 10 mg.
Prices, as last read on 21 Sep 2026: a median of $209.98 per mg and a lowest of $159.78 per mg on a 0.5 mg vial, across 4 comparable in-stock offers in sizes from 0.1 mg to 0.5 mg. Twenty-three shops are known to sell tesofensine, but most listings are multi-vial kits that cannot be compared per milligram, so that median rests on four offers. At the median a 0.5 mg container is $104.99 of compound. The figures exclude shipping, taxes, coupons, bulk tiers and kits; the full list is on the tesofensine price page.
Per the compound page, tesofensine is not approved by the FDA or EMA; as of 2026 it has no active US approval pathway and is not available by prescription in the United States. The furthest-advanced step is in Mexico, where COFEPRIS's technical committee issued a favorable opinion in February 2023 — but tesofensine remains not finally approved in Mexico, or anywhere else, as of August 2026. Tesomet, tesofensine combined with the beta-blocker metoprolol, is a separate, still-investigational programme and is not approved in any market. Elsewhere tesofensine circulates as a research-use-only compound. Country rules: regulatory status by country.
Independent test records: tesofensine lab tests. How to read a certificate for a small molecule — HPLC purity plus mass-spectrometry identity against 328.28 Da: reading lab test results.
Peptigrity does not state one. The compound page's answer is: 'No. Tesofensine is not approved for human consumption, is active at sub-milligram doses, and carries a documented cardiovascular safety signal.' Peptigrity does not recommend a dose; the doses studied in the 2008 TIPO-1 Phase II trial were 0.5 mg and 1.0 mg, and trial doses across studies ranged from roughly 0.25 to 1 mg - figures from research, not a recommendation.
No. It is a small-molecule phenyltropane, C17H23Cl2NO, 328.28 g/mol, and a triple monoamine reuptake inhibitor. It appears on Peptigrity because it is sold in the same research-compound market as peptides, not because of any structural similarity.
The compound page names oral product forms only - capsules, tablets and oral solution - and no injectable route, so there is nothing to measure on a syringe. The calculator divides a labelled container by an amount you enter.
A median of $209.98 per mg and a lowest of $159.78 per mg on a 0.5 mg vial, across 4 comparable in-stock offers, as last read on 21 September 2026. A 0.5 mg container is therefore about $104.99 of compound at the median. The median rests on four offers, and the figures exclude shipping, taxes, coupons, bulk tiers and multi-vial kits.
The four tests on file all measured above label: 0.25 mg measured 0.27 mg (+8%), and three 0.5 mg containers measured 0.518, 0.52 and 0.54 mg (+3.6% to +8%). Four results is a small sample, and the compound page stresses that at sub-milligram amounts small labelling errors become large relative errors.